Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsProAssurance reports Q1 2026 net income of $8.5M as Doctors Company merger awaits final approvals
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Q1 net income $8.5M ($0.16) / operating income $12.7M ($0.25); combined ratio improved 2.3pts to 109.9% — still an underwriting loss; investment income +8.2%.
Exhibit 99.1 view on EDGAR → -
high
Segment split: Specialty P&C combined ratio improved to 105.9%; Workers' Compensation deteriorated to 114.1% — consolidated improvement was not uniform.
Exhibit 99.1 view on EDGAR → -
high
Doctors Company merger: six state approvals done (AL, DC, IL, MO, TX, VT); CA and PA pending; June 30, 2026 target, timing uncertain — per this press release's state-regulator update only.
Exhibit 99.1 view on EDGAR → -
medium
Specialty P&C renewal premiums +6% with 83% retention; MPL favorable prior-year reserve development $3.0M.
Exhibit 99.1 view on EDGAR → -
medium
BVPS $25.94 (from $26.24 YE); adjusted BVPS $27.86 (from $27.82).
Exhibit 99.1 view on EDGAR →
Summary
ProAssurance reported first-quarter 2026 results showing modest profitability: net income $8.5 million ($0.16/share) and operating income $12.7 million ($0.25/share). The consolidated combined ratio improved 2.3 points to 109.9% — still an underwriting loss (>100%), with net income driven by investment income (+8.2%), not underwriting profit.
Improvement was uneven: Specialty P&C strengthened (combined ratio 105.9%) while Workers' Compensation deteriorated (combined ratio 114.1%). Favorable MPL prior-year reserve development of $3.0 million helped the consolidated ratio (press release emphasis; consolidated net favorable development was higher).
On the pending Doctors Company merger, this press release reports six of eight state insurance-regulator approvals complete (Alabama, DC, Illinois, Missouri, Texas, Vermont) with California and Pennsylvania pending and a June 30, 2026 target acknowledged as uncertain — it does not discuss HSR/FTC early termination or the shareholder vote. Book value per share was $25.94 ($26.24 YE); adjusted BVPS $27.86 ($27.82). Results were furnished under Item 2.02 (Exhibit 99.1), not filed under Section 18. Signed by Jeffrey P. Lisenby, General Counsel.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $8.5 million, or $0.16 per diluted share, and operating income(1) was $12.7 million, or $0.25 per diluted share, for the three months ended March 31, 2026.
ProAssurance reported Q1 2026 net income of $8.5 million ($0.16 per diluted share) and operating income of $12.7 million ($0.25). The consolidated non-GAAP combined ratio improved 2.3 points to 109.9% — still above 100% (underwriting loss), with net income supported by investment income (+8.2%). Specialty P&C combined ratio improved to 105.9% while Workers' Compensation deteriorated to 114.1%. Favorable MPL prior-year reserve development of $3.0 million contributed to the consolidated improvement.
Added in current filing · view on EDGAR →
Closing the transaction remains subject to approval from insurance regulators in the jurisdictions where we have operating subsidiaries domiciled. To date, The Doctors Company has received final approval from insurance regulators in Alabama, the District of Columbia, Illinois, Missouri, Texas and Vermont. Review of the proposed transaction by insurance regulators remains pending in California and Pennsylvania. The timing for completion of the pending reviews is uncertain and outside our control, but in light of progress made, we continue to anticipate closing the transaction by June 30, 2026
The pending merger with The Doctors Company has received state insurance-regulator approvals in six jurisdictions (Alabama, DC, Illinois, Missouri, Texas, Vermont) but remains pending in California and Pennsylvania. The company continues to anticipate closing by June 30, 2026, though timing is uncertain and outside its control. This press release's merger discussion covers those state approvals only — it does not disclose FTC/HSR early termination or shareholder-vote outcomes; do not import those from outside this Exhibit 99.1.
Added in current filing · view on EDGAR →
Specialty P&C renewal premium increases of 6% for the quarter are part of the cumulative premium change of more than 80% we have accomplished since 2018 in the medical professional liability market. Retention for the entire Specialty P&C segment was 83% for the quarter, slightly lower than retention for full-year 2025. We continue to forgo renewal and new business opportunities when we believe they do not meet our expectation of rate adequacy in the current medical professional liability loss environment.
The Specialty P&C segment achieved 6% renewal premium increases in Q1 2026, contributing to cumulative premium increases exceeding 80% since 2018. Retention was 83%, slightly below full-year 2025 levels, as the company continues to decline business that does not meet rate adequacy expectations in the challenging medical professional liability environment.
Added in current filing · view on EDGAR →
Book value per share was $25.94 at March 31, 2026, down $0.30 from $26.24 at year-end 2025 due to changes in the market value of long-term investments; Non-GAAP adjusted book value per share(1) was $27.86 compared with $27.82 at year-end 2025.
Book value per share declined to $25.94 at March 31, 2026 from $26.24 at year-end 2025, primarily due to changes in the market value of long-term investments. Non-GAAP adjusted book value per share (which excludes accumulated other comprehensive income) increased slightly to $27.86 from $27.82.
Added in current filing · view on EDGAR →
The progress was largely due to the effect of favorable prior year reserve development, primarily related to $3.0 million of favorable development in our Medical Professional Liability business
The company recognized $3.0 million of favorable prior-year reserve development in its Medical Professional Liability business during Q1 2026, contributing to the improvement in the consolidated combined ratio. This favorable development indicates that prior-year loss reserves were adequate and claims settled for less than originally estimated.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 10, 2026 · How we verify